Myotonic Dystrophy Market Poised for Growth Amid Therapeutic Pipeline

The global market for myotonic dystrophy reached a valuation of USD 236 million in 2025, with the United States representing the largest segment. Currently, no approved therapies exist to cure the condition or halt its progression, leaving patients reliant on off-label symptomatic treatments such as mexiletine, anticonvulsants, and various muscle relaxants. This gap in the standard of care has spurred an intense research environment, with companies like AMO Pharma, Novartis, Avidity Biosciences, and Dyne Therapeutics pipeline-testing experimental drugs.

Increased genetic testing access and heightened disease awareness are driving earlier diagnoses, which in turn influences market demand. Emerging precision approaches—including antisense oligonucleotides and RNA-targeted therapies—are the primary catalysts for long-term growth. While some candidates have faced clinical hurdles, such as the recent Phase III trial outcome for Novartis’s delpacibart etedesiran, industry analysts suggest that the eventual arrival of durable, functional therapies will likely reshape reimbursement structures and clinical practice standards over the next decade.